Multicenter clinical trial: treatment effect of lansoprazole on non-traumatic osteonecrosis of the femoral head

Multicenter clinical trial: treatment effect of lansoprazole on non-traumatic osteonecrosis of the femoral head - Clinical trial for treatment effect of non-traumatic osteonecrosis of the femoral head

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032412

Enrollment

100

Registered

2018-04-27

Start date

2016-08-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic osteonecrosis of the femoral head

Interventions

Lansoprazole 30mg orally once a day for one year No administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Japanese patients diagnosed with non-traumatic osteonecrosis of the femoral head. 2. Osteonecrosis of the femoral head meets the diagnosis criteria for that condition and is Stage I or II and Type A-C2.

Exclusion criteria

Exclusion criteria: 1. Patients with pain suggesting femoral head collapse (Stage III). 2. Patients underwent hip surgery. 3.Patients with alcohol-abuse or dementia 4. Past allergy to lansoprazole. 5. Patients treatment with atazanavir sulfate (Reyataz).

Design outcomes

Primary

Measure	Time frame
The reduction rate of non-traumatic osteonecrosis of the femoral head by MRI after 6 months and 1 year.	—

Countries

Japan

Contacts

Public ContactIma Kosukegawa

Sapporo Medical University Dept. of Orthopedic Surgery

imakosukegawa@gmail.com+81-11-611-2111(33330)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026